Press release
Deadline on Nov. 16th coming up in Lawsuit for Investors in Odonate Therapeutics, Inc. (NASDAQ: ODT) shares
A Deadline is coming up on November 16, 2020 in the lawsuit for certain investors in Odonate Therapeutics, Inc. (NASDAQ: ODT).
Investors who purchased shares of Odonate Therapeutics, Inc. (NASDAQ: ODT) have certain options and there are strict and short deadlines running. Deadline: November 16, 2020. NASDAQ: ODT stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the Southern District of California the plaintiff alleges on behalf of purchasers of Odonate Therapeutics, Inc. (NASDAQ: ODT) common shares between December 7, 2017, and August 21, 2020, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between December 7, 2017, and August 21, 2020, the Defendants made false and/or misleading statements and/or failed to disclose that tesetaxel was not as safe or well-tolerated as the Company had led investors to believe, that consequently, tesetaxel's commercial viability as a cancer treatment was overstated, and that as a result, the Company's public statements were materially false and misleading at all relevant times.
Those who purchased shares of Odonate Therapeutics, Inc. (NASDAQ: ODT) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Deadline on Nov. 16th coming up in Lawsuit for Investors in Odonate Therapeutics, Inc. (NASDAQ: ODT) shares here
News-ID: 2181844 • Views: …
More Releases from Shareholders Foundation
Investigation announced for Long-Term Investors in shares of West Pharmaceutical …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of West Pharmaceutical Services, Inc..
Investors who are current long term investors in West Pharmaceutical Services, Inc. (NYSE: WST) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in (NYSE: WST stocks follows a lawsuit filed…
Investigation announced for Long-Term Investors in Open Lending Corporation (NAS …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Open Lending Corporation.
Investors who are current long term investors in Open Lending Corporation (NASDAQ: LPRO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: LPRO stocks follows a lawsuit filed against Open…
Investigation announced for Long-Term Investors in shares in BigBear.ai Holdings …
An investigation on behalf of current long-term investors in shares of BigBear.ai Holdings, Inc. (NYSE: BBAI) concerning potential breaches of fiduciary duties by certain directors and officers of BigBear.ai Holdings, Inc. was announced.
Investors who are current long term investors in BigBear.ai Holdings, Inc. (NYSE: BBAI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm…
Lawsuit filed for Investors who lost money with shares of DoubleVerify Holdings, …
An investor, who purchased shares of DoubleVerify Holdings, Inc. (NYSE: DV), filed a lawsuit over alleged violations of Federal Securities Laws by DoubleVerify Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of DoubleVerify Holdings, Inc. (NYSE: DV) have certain options and for certain investors are short and strict deadlines running. Deadline: July 21, 2025. NYSE: DV investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Odonate
Metastatic HR+/HER2- Breast Cancer Market: Analysis of Epidemiology, Pipeline Pr …
Metastatic HR+/HER2- Breast Cancer emerging therapies such as KISQALI (ribociclib), PIQRAY (alpelisib), ARV-471 (vepdegestrant), OP1250 (palazestrant), and others are expected to boost the Metastatic HR+/HER2- Breast Cancer Market in the upcoming years.
DelveInsight has launched a new report on "Metastatic HR+/HER2- Breast Cancer - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Metastatic HR+/HER2- Breast Cancer, historical and forecasted epidemiology as well as the Metastatic HR+/HER2-…
HR+/HER2- Breast Cancer Market Is Booming Worldwide | Latest Study Reveal for th …
HR+/HER2- Breast Cancer Market business research report assesses the current as well as upcoming performance of the market, also brand-new trends in the market. It provides product overview and highlights of product and application segments of the market including price, revenue, sales, sales growth rate, and market share by product. The market statistics within the report is displayed in a statistical format to offer a better understanding upon the market…
Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breas …
DelveInsight's "Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer, historical and forecasted epidemiology as well as the Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United…
Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breas …
DelveInsight's "Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer, historical and forecasted epidemiology as well as the Hormone Receptor (HR) Positive/ Human Epidermal Receptor 2 (HER2) Negative Breast Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United…
Investigation announced for Long-Term Investors in shares of Odonate Therapeutic …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Odonate Therapeutics, Inc..
Investors who are current long term investors in Odonate Therapeutics, Inc. (NASDAQ: ODT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: ODT stocks follows a lawsuit filed against Odonate…
HER2-Positive Breast Cancer Market Newer segments of application 2030 | Merck, J …
HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. According to International Agency for Research on Cancer (IARC) published by the World Health Organization (WHO) in 2018, approximately 627,000 deaths every year. The incidence of nmCRPC in the United States is about 50,000–60,000 cases per year. Moreover, human epidermal growth factor receptor helps breast divide, cells grow, and repair.…
